PMID- 26373279
OWN - NLM
STAT- MEDLINE
DCOM- 20151204
LR  - 20220330
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 28
IP  - 3
DP  - 2015 Sep 14
TI  - Spatiotemporal Evolution of the Primary Glioblastoma Genome.
PG  - 318-28
LID - S1535-6108(15)00265-2 [pii]
LID - 10.1016/j.ccell.2015.07.013 [doi]
AB  - Tumor recurrence following treatment is the major cause of mortality for 
      glioblastoma multiforme (GBM) patients. Thus, insights on the evolutionary 
      process at recurrence are critical for improved patient care. Here, we describe 
      our genomic analyses of the initial and recurrent tumor specimens from each of 38 
      GBM patients. A substantial divergence in the landscape of driver alterations was 
      associated with distant appearance of a recurrent tumor from the initial tumor, 
      suggesting that the genomic profile of the initial tumor can mislead targeted 
      therapies for the distally recurred tumor. In addition, in contrast to 
      IDH1-mutated gliomas, IDH1-wild-type primary GBMs rarely developed hypermutation 
      following temozolomide (TMZ) treatment, indicating low risk for TMZ-induced 
      hypermutation for these tumors under the standard regimen.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Kim, Jinkuk
AU  - Kim J
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351, 
      Korea; Samsung Advanced Institute of Technology, Samsung Electronics Co., Ltd., 
      Seoul 06351, Korea.
FAU - Lee, In-Hee
AU  - Lee IH
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351, 
      Korea; Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
FAU - Cho, Hee Jin
AU  - Cho HJ
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351, 
      Korea; Department of Health Sciences and Technology, Samsung Advanced Institute 
      for Health Science and Technology (SAIHST), Sungkyunkwan University, Seoul 06351, 
      Korea.
FAU - Park, Chul-Kee
AU  - Park CK
AD  - Department of Neurosurgery, Seoul National University Hospital, Seoul National 
      University College of Medicine, Seoul 06351, Korea.
FAU - Jung, Yang-Soon
AU  - Jung YS
AD  - Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University 
      School of Medicine, Seoul 06351, Korea.
FAU - Kim, Yanghee
AU  - Kim Y
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351, 
      Korea.
FAU - Nam, So Hee
AU  - Nam SH
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351, 
      Korea.
FAU - Kim, Byung Sup
AU  - Kim BS
AD  - Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University 
      School of Medicine, Seoul 06351, Korea.
FAU - Johnson, Mark D
AU  - Johnson MD
AD  - Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA.
FAU - Kong, Doo-Sik
AU  - Kong DS
AD  - Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University 
      School of Medicine, Seoul 06351, Korea.
FAU - Seol, Ho Jun
AU  - Seol HJ
AD  - Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University 
      School of Medicine, Seoul 06351, Korea.
FAU - Lee, Jung-Il
AU  - Lee JI
AD  - Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University 
      School of Medicine, Seoul 06351, Korea.
FAU - Joo, Kyeung Min
AU  - Joo KM
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351, 
      Korea; Department of Health Sciences and Technology, Samsung Advanced Institute 
      for Health Science and Technology (SAIHST), Sungkyunkwan University, Seoul 06351, 
      Korea; Department of Anatomy and Cell Biology, Sungkyunkwan University School of 
      Medicine, Seoul 06351, Korea.
FAU - Yoon, Yeup
AU  - Yoon Y
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351, 
      Korea; Department of Health Sciences and Technology, Samsung Advanced Institute 
      for Health Science and Technology (SAIHST), Sungkyunkwan University, Seoul 06351, 
      Korea.
FAU - Park, Woong-Yang
AU  - Park WY
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351, 
      Korea; Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea; 
      Department of Health Sciences and Technology, Samsung Advanced Institute for 
      Health Science and Technology (SAIHST), Sungkyunkwan University, Seoul 06351, 
      Korea.
FAU - Lee, Jeongwu
AU  - Lee J
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research 
      Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
FAU - Park, Peter J
AU  - Park PJ
AD  - Division of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA; 
      Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, 
      USA. Electronic address: peter_park@harvard.edu.
FAU - Nam, Do-Hyun
AU  - Nam DH
AD  - Samsung Biomedical Research Institute, Samsung Medical Center, Seoul 06351, 
      Korea; Department of Health Sciences and Technology, Samsung Advanced Institute 
      for Health Science and Technology (SAIHST), Sungkyunkwan University, Seoul 06351, 
      Korea; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan 
      University School of Medicine, Seoul 06351, Korea. Electronic address: 
      nsnam@skku.edu.
LA  - eng
SI  - GEO/GSE63035
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
RN  - EC 1.1.1.42. (IDH1 protein, human)
RN  - YF1K15M17Y (Temozolomide)
SB  - IM
MH  - Antineoplastic Agents, Alkylating/therapeutic use
MH  - Brain Neoplasms/drug therapy
MH  - Dacarbazine/analogs & derivatives/therapeutic use
MH  - Glioblastoma/drug therapy/*genetics
MH  - Glioma/genetics
MH  - Humans
MH  - Isocitrate Dehydrogenase/genetics
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/drug therapy/*genetics
MH  - Temozolomide
EDAT- 2015/09/17 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/09/17 06:00
PHST- 2014/11/07 00:00 [received]
PHST- 2015/06/10 00:00 [revised]
PHST- 2015/07/28 00:00 [accepted]
PHST- 2015/09/17 06:00 [entrez]
PHST- 2015/09/17 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S1535-6108(15)00265-2 [pii]
AID - 10.1016/j.ccell.2015.07.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2015 Sep 14;28(3):318-28. doi: 10.1016/j.ccell.2015.07.013.